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mented as an important therapeutic goal in limiting left
ventricular (LV) dysfunction and arrhythmia,11,12 the
mechanism of this cardioprotective response is not well
understood. Data from several in vivo and in vitro mod-
els of IR injury suggest that free radicals and disruption
of metabolic homeostasis are important contributory
factors in myocardial cell death. Thus cytoprotection is
thought to involve increased expression of proteins that
either suppress free radical accumulation such as super-
oxide dismutase and catalase6,13,14 or maintain metabol-
ic homeostasis.1,5,7,10,15 However, several agents can
induce delayed ischemic tolerance in intact myocardi-
um6,16,17 without increasing the expression of antioxi-
dants and stress-response proteins.5,16,17 Whether these
diverse agents activate a common protective mechanism
P revious work suggests that pharmacologic interven-tions1-8 and short periods of ischemia-reperfusion
(IR)9,10 can limit myocardial infarction 24 hours later.
Although restriction of the infarcted area is well docu-
Objective: Previous studies have demonstrated that a 1-adrenoceptor acti-
vation increases myocardial resistance to ischemic injury 24 hours later.
Here we tested the hypothesis that delayed protection is associated with lim-
ited infarction and involves altered expression of pro-apoptotic and/or anti-
apoptotic proteins. Methods: Rabbits were treated with phenylephrine or
an equivalent volume of vehicle (n = 6 per group). Twenty-four hours
after pretreatment, isolated hearts were perfused with a bovine ery-
throcyte suspension in modified Krebs solution, subjected to 45 minutes
of global ischemia (37°C), and reperfused for 120 minutes. Infarct size
was determined by triphenyltetrazolium chloride staining. Apoptosis
was quantified by terminal deoxynucleotidyl transferase–mediated
dUTP nick end labeling. Left ventricular tissue from separate groups of
animals (n = 5 per group), 24 hours after pretreatment with phenyl-
ephrine or vehicle but without ischemia and reperfusion, was analyzed
by Western blotting for content of the anti-apoptotic protein, bcl
x
, and
pro-apoptotic protein, bax. Results: Isolated hearts after phenylephrine
pretreatment had increased end-reperfusion developed pressures (56.8 ±
4.9 vs 36.2 ± 3.9 mm Hg for vehicle, P = .008) and decreased elevated
end-diastolic pressures (26.7 ± 4.5 vs 42.3 ± 5.0 mm Hg for vehicle, P =
.04). Phenylephrine pretreatment abrogated infarction (9.9 ± 2.4% vs
42.6 ± 6.3% for vehicle, P = .002) and reduced the number of apoptotic
nuclei (24 ± 4.8 vs 51 ± 4.6 for vehicle, P = .038). Analysis by Western
blotting showed that the ratio of bcl
x
to bax protein increased in
phenylephrine-pretreated hearts (2.65 ± 0.5 vs 1.0 ± 0.1 for vehicle, P =
.008). Conclusion: Delayed myocardial protection to infarction mediated
by a 1-adrenoceptor activation involves an increased bcl
x
/bax ratio, thereby
limiting apoptotic cell death. (J Thorac Cardiovasc Surg 1999;117:980-6)
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and what factors mediate delayed protection remain
unknown. 
Myocardial infarction in reperfused ischemic
myocardium results from regulated cell death (apoptot-
ic) and unregulated cell death (non-apoptotic).18,19
Whereas non-apoptotic cell death is rapid, the initiation
and execution of apoptotic cell death is a slower process
involving multiple pathways. Common to all of these
pathways is the activation of proteases, called caspases.
In response to oxidative stress, the regulation and initia-
tion of caspase activity is governed by the bcl-2 family
of proteins,17,18 which either retard (eg, bcl-2, bcl
x
) or
promote (eg, bax) apoptosis. Thus the question arises as
to whether cardioprotective agents inhibit caspase activ-
ity and thereby infarction by altering the ratio of anti-
apoptotic protein(s) to pro-apoptotic protein(s). If so,
then modulation of bcl-2 gene products may provide a
general mechanism of delayed cardiac protection.
Here we determined whether a 1-adrenoceptor activa-
tion confers delayed ischemic tolerance to the myocyte
by modulating the ratio of the anti-apoptotic protein,
bcl
x
, to the pro-apoptotic protein, bax, thereby limiting
apoptosis. 
Methods
The animal protocol was reviewed and approved by the
Animal Care and Research Committee of the Medical
College of Virginia/Virginia Commonwealth University. All
animals received humane care in compliance with the “Guide
for the Care and Use of Laboratory Animals” (NIH
Publication No. 85-23, revised 1985).
Experimental protocols. Two experimental protocols
were used (Fig 1). In protocol 1, New Zealand White rabbits
(n = 12, 3-4 kg) were randomly assigned to 1 of 2 groups:
phenylephrine pretreatment (50 m g/kg, intravenously) or
saline vehicle (n = 6 per group). Successful activation of the
a -adrenoceptors was confirmed in pilot studies where
phenylephrine bolus administration caused a near doubling of
the mean arterial pressure that gradually returned to baseline
over the next 15 minutes. Twenty-four hours later, isolated
hearts were perfused as described below. The isolated hearts
underwent 60 minutes of equilibration during which the
intraventricular balloon was incrementally inflated until a sta-
ble diastolic pressure of 5-10 mm Hg was reached.
Subsequently, the hearts underwent 45 minutes of normoth-
ermic global ischemia followed by 120 minutes of reperfu-
sion. At the end of reperfusion, hearts were rapidly harvested
Fig 1. Treatment protocols used. In protocol 1, isolated hearts undergo global ischemia (time [0]) and reperfusion
24 hours after phenylephrine or vehicle pretreatment. In protocol 2, hearts are harvested 24 hours after pretreat-
ment for molecular studies. 
Fig 2. Comparison of diastolic (circles) and systolic
(squares) pressures in isolated hearts subjected to ischemia
and reperfusion 24 hours after pretreatment with phenyl-
ephrine (solid lines) and vehicle (dotted lines). Time (0)
denotes onset of ischemia followed by reperfusion 45 min-
utes later. Data points are pressure ± SEM. Asterisk (*)
denotes significant differences compared with time-matched
EDPs after vehicle pretreatment (t test, n = 6).
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and LV tissue rapidly processed for triphenyltetrazolium
chloride (TTC) and terminal deoxynucleotidyl transferase-
mediated dUTP nick end labeling (TUNEL). 
In protocol 2, rabbits were randomly assigned to 1 of 2
groups: phenylephrine pretreatment (50 m g/kg, intravenously)
or saline vehicle (n = 5 per group). Twenty-four hours later,
each rabbit was anesthetized with pentobarbital (65 mg/kg,
intravenously) and given heparin (1000 U/kg, intravenously).
The heart was excised. The LV was rapidly divided and frozen
in liquid nitrogen for analysis by Western blotting.
Isolated heart model. Experiments using an isolated beat-
ing rabbit heart preparation were performed as described pre-
viously by our group.20 In brief, rabbits were anesthetized
with a ketamine/xylazine mixture (50 mg/kg, 25 mg/kg,
intramuscularly, respectively), ventilated with oxygen, and
heparinized (1000 U/kg, intravenously). A thoracotomy was
performed followed by cardiectomy in rapid sequence.
Retrograde coronary perfusion was established via the aortic
root (100 cm H2O) with a total ischemic period of less than
30 seconds. The perfusate consisted of modified Krebs-
Henseleit buffer (NaCl 103 mmol/L, KCl 4.0 mmol/L,
KH2PO4 1.2 mmol/L, NaHCO3 30 mmol/L, MgSO4 1.2
mmol/L, ethylenediaminetetraacetic acid 0.4 mmol/L, lactate
1.0 mmol/L, dextrose 11 mmol/L, palmitic acid 0.4 mmol/L,
and albumin 4 g/dL) containing bovine erythrocytes at a
hematocrit value of 40%. An LV vent was placed in the apex.
A water-filled latex balloon connected to a pressure trans-
ducer and chart recorder (Gould, Inc, Cleveland, Ohio) was
inserted into the LV through the mitral orifice and secured
with a purse-string suture. The pulmonary artery was cannu-
lated for collection of coronary venous flow and the instru-
mented heart was submerged in saline solution (37°C).
Before and periodically during the experiment, blood gas val-
ues were measured and maintained within the normal physi-
ologic range. The hearts were paced at 180 beats/min (SDS9
Stimulator, Grass Instrument Co, Quincy, Mass). Physiologic
data including heart rate, diastolic pressure, systolic pressure,
and coronary flow were measured at the end of equilibration,
ischemia, and every 15 minutes during reperfusion.
TTC staining. For evaluation of cellular necrosis, the iso-
lated hearts pretreated with phenylephrine or saline vehicle
and subjected to protocol 1 were stained with TTC according
to the method of Fishbein and associates.21 In brief, the hearts
were rinsed with chilled saline solution and the atria and
approximately 3 mm of the apex were removed. The remain-
ing LV tissue was divided into 5 transverse slices (5-mm
thick), immersed in 1% TTC for 20 minutes (37°C), followed
by fixation in 10% formalin (60 minutes) and then pho-
tographed. Viable tissue stains red in this assay and infarcted
areas are nonstaining (white). 
TUNEL. In the same hearts subjected to protocol 1, apop-
tosis was measured. For this assay, the middle (third) slice of
unfixed LV, before processing for TTC staining, was used. LV
slices were immersed in 5% paraformaldehyde for 60 min-
utes (at 23°C) and then impregnated with 30% sucrose in
phosphate-buffered saline solution (4°C) over night. Slices
Fig 3. Left ventricular sections stained with TUNEL and Fl-dUTP after ischemia and reperfusion 24 hours after
pretreatment. No counterstain was used to allow clear identification of positive staining nuclei for apoptosis
(arrows). a, Vehicle. b, Phenylephrine. c, No nuclei are stained in the absence of deoxynucleotidyl transferase
(negative control). Bar = 55 µm.
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were frozen in liquid nitrogen and cyrosectioned. Next, 10- to
15-m sections were assayed by TUNEL staining according to
the manufacturer’s instructions (Apoptosis Detection System,
Promega, Madison, Wis) and visualized by either fluores-
cence microscopy (Zeiss, 25· lens, 0.8 NA; Carl Zeiss,
Oberkochen, Germany) or confocal microscopy (Zeiss
LSM410, 40· lens, 1.25 NA). The Promega TUNEL assay
has been widely used and validated in detection of apoptosis
in a variety of cell lines by many investigators.22 The number
of nuclei labeled with fluorescein-dUTP (Fl-dUTP) per unit
area of tissue was determined by counting an average of 9
high-power fields (31· ).
Western blotting. LV tissue samples (2 mg) from hearts
subjected to protocol 2 were pulverized under liquid nitrogen,
resuspended in sodium dodecyl sulfate (SDS) sample buffer
(400 m L, SDS 5%, Tris HCl 0.125 mmol/L, NaOH 6.25
mmol/L, glycerol 10%, b -mercaptoethanol 0.25%, and bro-
mophenol blue 1.25%). Equivalent samples (200 m g) were
subjected to SDS-PAGE (8% polyacrylamide gel elec-
trophoresis).23 Proteins were transferred over night at 4°C to
nitrocellulose membranes. Nonspecific protein binding was
blocked with Blotto (Tris HCl 50 mmol/L, NaCl 150 mmol/L,
Tween 0.05%, and powdered milk 5%, NaN3 0.02%). To
detect specific proteins, we then incubated the blots with
either mouse anti-bcl
x
antibody (1:500, Transduction Lab-
oratories, Lexington, Ky), or rabbit anti-bax polyclonal anti-
bodies (N20, 1:500, Santa Cruz Biotechnology, Santa Cruz,
Calif). We screened 2 antibodies directed to different primary
sequences (Santa Cruz N20 and P19) and found a positive
signal with N20. The specificity of the immunologic reaction
was controlled by preabsorbing the primary antibody with the
corresponding synthetic antigen and by omitting the primary
antibody (negative controls). Under these conditions, no spe-
cific signal was detected. As a positive control, we used
lysates of Nb2FMM lymphoma cells (gift of Dr Witorsch,
Medical College of Virginia, Virginia Commonwealth Uni-
versity). Bound antibody was detected with biotinylated sec-
ondary antibody (Vector Laboratories, Burlingame, Calif)
and enhanced chemiluminescence reagents (Nycomed
Amersham, Buckinghamshire, United Kingdom) according
to manufacturer’s recommendations. Total protein was mea-
sured by a commercial Protein Assay kit (Sigma Chemical
Co, St Louis, Mo).
Data analysis. Data shown are expressed as the mean ±
SEM. The number of hearts used is indicated. Auto-
radiographs were analyzed with the Photoshop Image analyz-
ing program (Adobe Systems Incorporated, San Jose, Calif).
Integrated densities of autoradiographic bands were deter-
mined as a function of pixel intensity per unit area.
Developed pressure (DP) was calculated as systolic minus
diastolic pressure at each time point. The percent infarcted
area was calculated as the ratio of the infarcted to total area at
risk. Nested analysis of variance and Bonferroni post hoc test
(SAS STATVIEW, SAS Institute, Inc, Cary, NC) determined
significant differences within multiple groups. Significant
differences between 2 experimental groups were determined
by the Student t test. The correlation between infarction and
functional parameters was determined by the Pearson product
moment test (SigmaStat, Jandel Scientific, SPSS, Inc,
Chicago, Ill).
Results
Phenylephrine pretreatment blunts contractile
dysfunction by IR. The baseline systolic and diastolic
pressures for the phenylephrine- and vehicle-pretreated
isolated hearts did not differ significantly at the end of
the 60-minute equilibration period. However, phenyl-
ephrine-pretreated hearts had significantly less contrac-
ture at the end of the ischemic period (38.7 ± 6.4 vs
55.5 ± 2.6 mm Hg for vehicle, P = .034). Additionally,
they had better DPs at end-reperfusion (56.8 ± 4.9 vs
36.2 ± 3.9 mm Hg for vehicle, P = .008). The improved
DP was primarily due to better resolution of the
postreperfusion elevated end-diastolic pressure (EDP)
in the phenylephrine-pretreated hearts (26.7 ± 4.5 vs
42.3 ± 5.0 mm Hg for vehicle, P = .042). The systolic
pressures for the 2 groups were similar (Fig 2).
Phenylephrine pretreatment limits IR-induced
infarction. The fraction of infarcted myocardium in
hearts subjected to protocol 1 was determined using
TTC-stained LV sections. Infarction was significantly
reduced after phenylephrine pretreatment (9.9% ± 2.4%
vs 42.6% ± 6.3% for vehicle, P = .002). The reduction
in infarction positively correlated with the reduction in
Fig 4. Confocal micrograph of TUNEL-stained end-reperfu-
sion myocardium 24 hours after vehicle pretreatment.
TUNEL-positive DNA fragmentation is shown in myocyte
(**) and endothelial (*) nuclei. Bar = 100 µm.
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end-ischemic contracture (R = +0.68, P = .03) and end-
reperfusion EDP (R = +0.74, P = .02) as determined by
the Pearson product moment. Additionally, a significant
negative correlation was present between infarction and
end-reperfusion DPs (R = –0.84, P = .002).
Phenylephrine pretreatment decreases apoptosis.
Apoptotic nuclei are represented by bright spots on
TUNEL-stained sections (Fig 3). The number of apop-
totic nuclei significantly decreased after pretreatment
with phenylephrine (24 ± 4.8 vs 51 ± 4.6 per high-power
field for vehicle, P = .038). Confocal microscopy identi-
fied apoptotic endothelial cells in addition to myocytes.
It also demonstrated condensed nuclear chromatin with
fragmentation (typical apoptotic characteristics) in
TUNEL-positive myocyte nuclei (Fig 4). When further
analyzed by the Bonferroni post hoc test, each phenyl-
ephrine-pretreated heart differed significantly from its
matched control. No significant differences were found
among the phenylephrine-pretreated hearts; one of the
control hearts did differ significantly from the others.
Phenylephrine pretreatment alters levels of bax
but not bcl
x
proteins. The protein contents for bax and
bcl
x
were determined in hearts subjected to protocol 2.
Autoradiographs generated using Western blot analyses
of LV tissue in hearts 24 hours after phenylephrine and
vehicle treatment are shown in Fig 5. The average den-
sitometric scores for bax and bcl
x
protein contents are
summarized in Fig 6. The phenylephrine- and vehicle-
pretreated hearts had similar levels of bcl
x
(195.8 ± 8.1
and 173.8 ± 17.7, respectively, P = not significant).
Phenylephrine-pretreated hearts had lower levels of
bax protein (86.2 ± 17.0 vs 175.8 ± 12.4 for vehicle, P
= .003). The averaged ratios of bcl
x
to bax protein con-
tent more than doubled after phenylephrine pretreat-
ment (2.6 ± 0.5 vs 1.0 ± 0.1 for vehicle, P = .008). 
Discussion
Previous studies of regional ischemic injury have
shown that a 1-adrenoceptor activation can confer both
acute24 and delayed8 cardioprotection in the rabbit.
Here, we evaluated the a 1-adrenoceptor agonist,
phenylephrine, in mediating delayed protection to
global ischemia. We selected a pharmacologically
mediated model of delayed cardioprotection against
global IR injury in the rabbit because of its potential
clinical applicability in cardiac surgery. In addition,
global IR eliminates the inherent variability in measur-
ing regional myocardial function and the inevitable
limitations of extrapolated global function from region-
al data. Additionally, global IR in a larger animal model
would require cardiopulmonary bypass that may intro-
duce confounding variables associated with extracor-
poreal circulation.
Our findings showed improved postreperfusion dia-
stolic recovery (decreased EDP) and contractile func-
tion (increased DP) in hearts 24 hours after pretreat-
ment with phenylephrine. This effect was associated
with a significant reduction in infarction. This reduc-
tion in cell death directly correlated with improved
Fig 5. Autoradiographs depict Western blot analyses of rabbit myocardium 24 hours after pretreatment with
phenylephrine or vehicle for bax and bcl
x
protein levels. The molecular weight of the specific bands on the gel is
noted to the right.
Fig 6. Bar graphs represent the average densitometric scores
derived from the Western blot analyses for myocardial bax
and bcl
x
protein contents. Two pretreatment groups were ana-
lyzed: vehicle (black) and phenylephrine (white). Asterisks
(**) denote significant difference compared with vehicle, P =
.003 (t test, n = 5).
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global functional parameters, suggesting that cell death
is an important contributing factor to contractile
impairment. Our findings of improved diastolic func-
tion in this infarct model are in contrast to improved
systolic pressure associated with delayed precondition-
ing induced by brief IR in rabbits10 and pigs.25 These
findings suggest that the mechanisms limiting infarc-
tion in a 1-adrenoceptor—mediated delayed precondi-
tioning may be distinct from that initiated by periods of
IR. A possible explanation for this disparity in systolic
and diastolic protection may be that different precondi-
tioning methods recruit different endogenous protective
mechanisms, therefore influencing the extent and
nature of the preconditioning effect, such as differential
protection against infarction and stunning. Recent
unpublished data from our laboratory confirm a -adren-
ergic delayed preconditioning against infarction with-
out significant amelioration of stunning. 
In the heart, the a -adrenoceptor plays an important
role in myocyte growth. a -Adrenoceptor activation
triggers a sequel of cellular responses including activa-
tion of protein kinase C (PKC) and an increase in intra-
cellular calcium levels. In delayed cardioprotection by
repetitive IR periods, activation of PKC has been impli-
cated as a critical event25; however, the proteins that
mediate delayed preconditioning by ischemia are
unknown. In macrophages the PKC activator, 12-O-
tetradecanoylphorbol-13-acetate, blocks nitric oxide
induced apoptotic DNA fragmentation and depresses
levels of bax protein.26 Because cell growth and cell
death are opposing and coupled processes, we asked
whether a 1-adrenoceptor activation by phenylephrine
affords cellular protection to ischemic injury. In partic-
ular, we studied its effects on regulated cell death.
Recent studies have demonstrated acute ischemic pre-
conditioning limiting IR-induced apoptosis.27 How-
ever, our current study is the first demonstration that
pharmacologic pretreatment limits apoptosis and
depresses levels of bax in the myocardium 24 hours
later. Although an active role for PKC in this phenom-
enon is suggested, the identity of the intracellular sig-
naling factors involved requires further investigation.
Using the TUNEL assay and confocal microscopy,
we have shown that global IR can initiate regulated cell
death in the isolated rabbit heart. Our findings support
those of others18,19 that demonstrate apoptosis within
cardiac myocytes in paradigms of ischemic injury.
Additionally, we showed apoptosis in endothelial cells
in the IR-injured myocardium. We found a significant
effect on TUNEL staining by phenylephrine 24 hours
after pretreatment, with the number of myocyte and
endothelial apoptotic nuclei markedly decreased.
Several hypotheses have been proffered to explain
delayed tolerance to IR injury. In general, protection is
thought to involve the induction of antioxidant path-
ways and increased expression of stress response pro-
teins. However, delayed cellular protection is not close-
ly correlated with increased expression of stress
response genes such as heat shock proteins and
SOD.1,5,17 Instead, our data suggest that a 1-adrenocep-
tor–mediated delayed preconditioning may confer pro-
tection by altering the levels of pro-apoptotic proteins
and thereby suppress programmed cell death.
Bax protein is found in various tissues including
myocytes of human hearts without cardiac disease.18,19
It is a member of a family of homologous proteins
(including bcl-2, bcl
x
) that encompasses 2 groups of
genes that govern apoptosis, including caspase-depen-
dent as well as oxidant- and hypoxia-induced cell
death. The anti-apoptotic proteins (bcl-2 and bcl
x
) pre-
vent cell death by binding the pro-apoptotic protein
(bax).18,19 Once complexed with bcl-2 or bcl
x
, bax is
inhibited. Conversely, the pro-apoptotic proteins such
as bax, when over expressed, can block the death
repressor activity of bcl-2 and bcl
x.
28-30 Therefore the
ratio of these gene products is a critical factor in deter-
mining whether the cell survives or dies.18,19,25-32 Cell
death can be delayed in ventricular myocytes31,32 by
suppressing the relative content of the pro-apoptotic
protein, bax. Consistent with these findings, we have
observed that transient a 1-adrenoceptor activation sup-
pressed bax protein levels 24 hours later without sig-
nificant changes in bcl
x
protein levels, thereby marked-
ly altering the bax to bcl
x
ratio favoring suppression of
apoptosis. The altered ratio was significantly associat-
ed with decreased post-IR apoptosis, infarction, and
global myocardial dysfunction. Whether the change in
bax protein level reflects decreased transcriptional
activity and/or increased turnover of the encoding mes-
senger RNA and/or protein is not known. Further stud-
ies are required to explore the regulatory mechanisms
involved in a 1-adrenoceptor–mediated suppression of
bax protein levels, in particular the role of PKC.
In summary, we conclude that increased bcl
x
/bax pro-
tein ratio is associated with myocardial tolerance to IR
injury 24 hours after a 1-adrenoceptor activation.
Although an increase in this ratio is sufficient to provide
cytoprotection, we cannot exclude other bcl
x
homolo-
gous proteins (eg, bcl-2, bad, fas, and bak) that may also
be involved. Our data implicate apoptosis as a contribu-
tory factor in the pathogenesis of IR-induced cell death
and suggest that targeted pharmacologic modulation of
apoptosis may provide new cardioprotection modalities
for use in cardiac surgical procedures.
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